Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin
Crossref DOI link: https://doi.org/10.1007/s12072-015-9654-9
Published Online: 2015-08-12
Published Print: 2016-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Nakayama, Masahiko
Kobayashi, Hisanori
Fukushima, Koji
Ishido, Miwako
Komada, Yuji
Yoshizawa, Kazutake
Funding for this research was provided by:
Janssen Pharmaceutical K.K.
License valid from 2015-08-12